Foundayo Ships Week 2: How to Order Eli Lilly's GLP-1 Pill Right Now (April 2026)
Verified April 11, 2026: Foundayo (orforglipron) shipped to LillyDirect patients starting April 6. First-week fill rate hit 94% within 48 hours of order. Pricing confirmed: $649/mo self-pay, $25/mo with commercial insurance + Lilly savings card. Here's exactly how to order today.
Summarize this article with
Verified April 11, 2026: Foundayo (orforglipron) began shipping through LillyDirect on April 6, 2026, five days after its April 1 FDA approval. First-week fill rate through LillyDirect hit approximately 94% within 48 hours of order per Eli Lilly's investor update. Confirmed April 2026 pricing: $649/month self-pay through LillyDirect, $25/month copay with commercial insurance plus the Lilly savings card, and telehealth rollout begins April 14. For context, injectable alternatives at lower price points: Enhance MD compounded tirzepatide from $99 first month (20.9% weight loss vs Foundayo's 12.4%) or Enhance MD compounded semaglutide from $49 first month. Foundayo is the first non-peptide GLP-1 pill, no fasting requirement, no injection, take any time of day.
Quick answer: how to get Foundayo this week.
- •LillyDirect (direct-to-consumer, $649/mo): Go to lilly.com/lillydirect/medicines/foundayo. Complete the 8-minute online medical intake. Ships in 3-5 days.
- •Commercial insurance + Lilly savings card ($25/mo): Get a prescription from your doctor. Activate the savings card at foundayo.lilly.com/savings. Fill at a retail pharmacy (CVS, Walgreens, Walmart), rollout completes by April 15.
- •Telehealth providers: LillyDirect is the only authorized channel this week. Telehealth availability begins April 14, expect Sprout Health, Enhance MD, and other established platforms to offer it first based on their Lilly relationships.
- •Medicare patients: Foundayo IS covered by the Medicare GLP-1 Bridge at $50/month for eligible Part D beneficiaries live as of July 1, 2026. Foundayo is one of four drugs included in the Bridge (alongside Wegovy injection, Wegovy oral, and Zepbound KwikPen). See our Bridge enrollment guide for eligibility requirements and the BMI-based routing rule.
- •Cash-pay backup if Foundayo is out of stock: NovoCare Wegovy $349/mo (oral or injectable) or LillyDirect Zepbound $299/mo starter vial. Lower-cost compounded alternatives: Enhance MD tirzepatide from $99 first month or Enhance MD semaglutide from $49 first month.
This is a rapid-response piece on the Foundayo launch. For the full clinical profile (12.4% body weight loss per ATTAIN-1, dosing schedule, side effects, comparison to Wegovy pill), see our complete Foundayo guide and the head-to-head Foundayo vs Wegovy Pill comparison.
Comparing your options?
See every verified GLP-1 program ranked side by side on cost, safety, and care quality.
Compare all 52GLP-1 providers →Why Foundayo Matters, The 48-Hour Story
Foundayo's approval and launch compressed a typical 12-18 month FDA-to-shelf cycle into 49 days total (filing to shipping). Eli Lilly used the FDA's National Priority Voucher program, which allows accelerated review for drugs meeting public health priorities. Obesity qualifies because 30M+ Americans are currently on GLP-1 therapy and demand far exceeds injectable capacity.
Three things made this launch unusually fast:
- •Manufacturing was ready. Lilly started scaling orforglipron production in Q3 2025 based on ACHIEVE-1 Phase 3 data, betting on approval. That bet paid off, LillyDirect had starter inventory before the FDA decision.
- •Non-peptide chemistry is easier to scale. Peptide drugs (semaglutide, tirzepatide) require complex bioreactor production. Orforglipron is a small molecule, synthesized via standard pharmaceutical chemistry at higher volumes per batch.
- •Direct-to-consumer channel was pre-built. LillyDirect launched for Zepbound in 2024, so the infrastructure (medical intake, prescriber network, pharmacy fulfillment) was already in place. Foundayo just plugged in.
Every Tuesday. One email. The cheapest verified GLP-1 programs of the week.
Price drops, FDA alerts, new programs ranked, and compounded shortages, delivered Tuesday morning. No filler. Unsubscribe anytime.
No affiliate spam. No retargeting pixels. Unsubscribe in one click.
What Early Patients Are Reporting (Week 1)
We monitored Reddit (r/Semaglutide, r/Ozempic, r/loseit, r/Foundayo) and X for April 6-11 posts from verified Foundayo patients. The sample is small and unscientific, but the themes are consistent:
- •Nausea is manageable. Most week-1 posts describe mild nausea lasting 24-48 hours after the first dose, then fading. This matches the ATTAIN-1 trial where 16.5% of patients reported nausea vs 4.1% for placebo.
- •The no-fasting pitch is real. Multiple posts emphasized taking Foundayo with coffee and breakfast, something impossible with oral Wegovy's 30-minute fasting window.
- •Appetite suppression kicks in by day 3-4. Similar timeline to injectable GLP-1s.
- •Shipping speed: Most LillyDirect orders arrived within 3-5 business days. A few delays to rural addresses pushed to 7 days.
Not sure which GLP-1 program is right for you?
Take the 60-second quiz, we'll match you against 52 verified providers on your goals, budget, and medication preference, then surface your top 3.
Take the 60-sec QuizPricing Reality Check: $649/mo vs the Alternatives
Foundayo's $649/month self-pay price is significantly higher than compounded alternatives but competitive with brand-name options in the same class:
| Medication | Form | Self-Pay Price | Trial Weight Loss |
|---|---|---|---|
| Foundayo (orforglipron) | Daily pill, no fasting | $649/mo (LillyDirect) | 12.4% (ATTAIN-1) |
| Oral Wegovy (semaglutide 25mg) | Daily pill, 30-min fast | $1,349/mo (list) | 16.6% (OASIS-1) |
| Injectable Wegovy | Weekly injection | $349/mo (NovoCare) | 14.9% (STEP-1) |
| Injectable Zepbound | Weekly injection | $299/mo (LillyDirect 2.5mg) | 20.9% (SURMOUNT-1) |
| Compounded semaglutide | Weekly injection | $146/mo (Yucca Health) | ~14% (comparable to brand) |
| Compounded tirzepatide | Weekly injection | $99 first mo, then $280/mo (Enhance MD) | ~20% (comparable to brand) |
The math: Foundayo is the most expensive GLP-1 per percent of weight loss at $52/month per percentage point, vs Zepbound at $14/month and compounded tirzepatide at $7/month. You're paying for convenience (no injection, no fasting), not efficacy.
For a full cost breakdown across every GLP-1 option, see our GLP-1 cost guide or use the cost calculator.
What to Watch Next
- •April 14, 2026: Telehealth rollout begins. Expect price competition as Sprout Health, Enhance MD, and other established platforms announce Foundayo programs.
- •April 15, 2026: Retail pharmacy distribution completes (CVS, Walgreens, Walmart). Insurance-covered patients should be able to fill at their usual pharmacy by April 16.
- •May 2026: Lilly earnings call will include first-month Foundayo revenue. Analysts are watching for signs that the pill is eating into Wegovy/Ozempic prescription share.
- •July 1, 2026 (UPDATE): Medicare GLP-1 Bridge is live and DOES cover Foundayo at $50/month for eligible Part D beneficiaries, CMS confirmed Foundayo as one of four Bridge-eligible drugs. Bridge enrollment guide →
- •June 1, 2026 (UPDATE): CVS Caremark added Foundayo to its standard commercial formulary ahead of the typical 3–6 month post-approval window, covering ~25–30 million Americans. CVS simultaneously announced Zepbound formulary restoration effective October 1. Express Scripts and OptumRx decisions pending as of June 2026.
Sources
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1), Wharton S, Aronne LJ, Stefanski A, et al. N Engl J Med 2025;393(18):1796-1806 (DOI: 10.1056/NEJMoa2511774)
- FDA Approves First New Molecular Entity Under National Priority Voucher Program, Foundayo, U.S. Food and Drug Administration, April 1, 2026
- LillyDirect Foundayo Product Page, Eli Lilly
- FDA National Priority Voucher Program, U.S. Food and Drug Administration
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any medication. Information is current as of the publication date but may change.
Affiliate Disclosure: Some links in this article are affiliate links. We may earn a commission if you sign up through our links, at no extra cost to you.
Find your GLP-1 program, our Top Pick is TrimRx
Our featured pick, drawn from our independent ranking of 52 verified providers, at $149/mo all-in.
Featured affiliate pick, we may earn a commission · scores set by our methodology, not payment
Compare every GLP-1 program in one place
See all 52 verified providers ranked side by side on price, medication, and our independent score, or jump straight to the cheapest verified prices.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
Saw Medicare mentioned in "Foundayo Ships Week 2: How to Order Eli Lilly's GLP-1 Pill Right Now (April 2026)"? Here's exactly what's covered, who qualifies, and how the $50/mo Bridge copay works from July 1, 2026.
Read the Medicare Coverage Guide →Foundayo vs Wegovy Pill (2026): 16.6% vs 12.4% Weight Loss, $149 vs $1,349/mo Self-Pay
GuidesFoundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required
ComparisonsOral GLP-1 Weight Loss Pills (2026): Foundayo, Oral Semaglutide (Wegovy) & All Options Compared
What the doctors say
Verbatim, independently sourced statements from named physicians and medical bodies, real clinicians quoted with their sources, not a single paid reviewer. General clinical context, not an endorsement of any provider.
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales – they are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
“More options for people with these challenging diseases will be very helpful, particularly if the new oral tablet medicines are priced reasonably.”
“People with overweight or obesity have individual preferences, and with oral semaglutide as a potential new treatment option, more of those who are not on treatment today may consider starting GLP-1 treatment.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.